The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
MedPage Today on MSN10h
FDA Expands Guselkumab Approval to Crohn's DiseaseThe FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the ...
Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration ...
Johnson & Johnson’s (J&J) Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults ...
Pharmaceuticals announced topline results from its Phase 1 study comparing pharmacokinetics between subcutaneous and intravenous ...
between subcutaneous (SC) and intravenous (IV) formulations of sabirnetug in healthy volunteers. Weekly SC administration of sabirnetug was well-tolerated with systemic exposure supporting further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback